[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
18 years - 100 years
All
Phase
N/A
1 Location
Brief description of study
The purpose of this research study is to test if an imaging drug, not approved by the Food and Drug Administration (FDA), called FES, is useful for evaluating your type of cancer and predicting how well your cancer responds to therapy.
Detailed description of study
This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body (metastatic).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: breast cancer
-
Age: 18 years - 100 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1705571295 (EAI142)
